This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Multiple myeloma (MM)	CC chemokine receptor 1 (CCR1; CD191)	<p>Mouse studies identified a CCR1 antagonist that could help treat MM and associated osteolytic bone disease. In a mouse model of MM, prophylactic or therapeutic administration of the CCR1 antagonist CCX721 decreased both tumor burden and osteolytic bone damage compared with vehicle control and had an effect comparable to that of Aclasta zoledronic acid. ChemoCentryx Inc. did not disclose next steps, which could include testing CCX721 in additional animal cancer models.</p> <p>ChemoCentryx and GlaxoSmithKline plc's CCX345, a CCR1 antagonist that is an analog of CCX721, is in Phase II testing to treat rheumatoid arthritis (RA).</p> <p>Novartis AG markets Aclasta zoledronic acid for multiple indications including osteoporosis and bone cancer.</p> <p><i>SciBX</i> 5(23); doi:10.1038/scibx.2012.595 Published online June 7, 2012</p>	Patent applications filed; licensed by GlaxoSmithKline	<p>Dairaghi, D.J. <i>et al. Blood</i>; published online May 22, 2012; doi:10.1182/blood-2011-10-384784</p> <p>Contact: Daniel J. Dairaghi, ChemoCentryx Inc., Mountain View, Calif. e-mail: ddairaghi@chemocentryx.com</p>